Other therapy.
Publication: J Surg Oncol. 2022;125:596โ602. Authors: Jennifer A. Crozier Read More
Publication: ESMO Breast 2024 Authors:ย Virginia F. Borges1, Elena Shagisultanova1, Read More
Publication: European Journal of Cancer 217 (2025) 115222 Authors: Read More
Source: San Antonio Breast Cancer Symposiumยฎ Authors: Robert Maganini, Read More
Publication: ESMO Open - Volume 9 - Issue 11 Read More
Publication: ESMO 2024 Authors: Sonya Reid, M.D., Jennifer G. Read More
Cureus, part of Springer Nature Author: Jiang et al.
Read MoreThe Breast 76 (2024) 103752 Author: Mansani et al.
Read More: Cost consequence model of the MammaPrintยฎ (70-gene signature) and 21-gene signature in Patients with primary HR+ HER2-, N1 early-stage breast cancer in Germany
Read MoreSSO 2024 Author: Solis-Pomales et al.
Read More
Contact
For the US, Puerto Rico, Canada
and South America
Agendia Inc. USA, 22 Morgan, Irvine, CA 92618
(888) 321-2732
customercare@agendia.com
For outside the Americas
Agendia NV, Radarweg 60, 1043 NT Amsterdam, The Netherlands
+31 (0)20 462 1510
customerservice@agendia.com
ยฉ2025 Agendia. All rights reserved. MammaPrint and Blueprint are registered trademarks of Agendia, Inc.
CHIEF COMPLIANCE OFFICER
Stephanie has worked in compliance since 2005 and has extensive experience developing and managing programs to support compliance with global, federal, and state laws and regulations in the healthcare and biotech industries. Prior to joining Agendia, Stephanie spent a significant portion of her career serving as a compliance officer in laboratories, such as HealthTrackRx, NeoGenomics, and Myriad Genetics, and held compliance leadership roles in medical device, pharma, and large health systems.
Stephanie graduated Summa Cum Laude with a B.S. in Healthcare Administration from Northern Illinois University and is Certified in Healthcare Compliance (CHC), Data Privacy (CHP), Research Compliance (CHRC), and is a Certified Internal Auditor (CIA).
